Technical Analysis for ALNA - Allena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.42 6.77% 0.09
ALNA closed up 6.77 percent on Tuesday, August 4, 2020, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical ALNA trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish 6.77%
Stochastic Buy Signal Bullish 6.77%
Wide Bands Range Expansion 6.77%
Oversold Stochastic Weakness 6.77%
Narrow Range Bar Range Contraction 14.52%
Wide Bands Range Expansion 14.52%
Down 3 Days in a Row Weakness 14.52%
Down 4 Days in a Row Weakness 14.52%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Allena Pharmaceuticals, Inc. is a United States-based specialty biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.
Medicine Biopharmaceutical Medical Specialties Organ Systems Kidney Diseases Anticoagulants Hyperoxaluria

Is ALNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 6.3
52 Week Low 0.525
Average Volume 1,616,963
200-Day Moving Average 2.11
50-Day Moving Average 1.69
20-Day Moving Average 1.52
10-Day Moving Average 1.45
Average True Range 0.18
ADX 17.24
+DI 25.72
-DI 23.15
Chandelier Exit (Long, 3 ATRs ) 1.80
Chandelier Exit (Short, 3 ATRs ) 1.74
Upper Bollinger Band 2.00
Lower Bollinger Band 1.04
Percent B (%b) 0.4
BandWidth 63.49
MACD Line -0.09
MACD Signal Line -0.06
MACD Histogram -0.026
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.65
Resistance 3 (R3) 1.63 1.54 1.61
Resistance 2 (R2) 1.54 1.48 1.55 1.59
Resistance 1 (R1) 1.48 1.45 1.51 1.50 1.58
Pivot Point 1.39 1.39 1.41 1.40 1.39
Support 1 (S1) 1.33 1.33 1.36 1.35 1.26
Support 2 (S2) 1.24 1.30 1.25 1.25
Support 3 (S3) 1.18 1.24 1.23
Support 4 (S4) 1.20